6565 Results

People

  1. Gonen
    Gonen
  2. Panageas
    Panageas
  3. Patil
    Patil
  4. Giralt
    Giralt
  5. Zhang
    Zhang
  6. Heller
    Heller
  7. Devlin
    Devlin
  8. Seshan
    Seshan
  9. Jarnagin
    Jarnagin
  10. D'Angelica
    D'Angelica

Groups

  1. Biostatistics Service (6565)
  2. Epidemiology and Biostatistics (6565)
  3. Department of Medicine (3849)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2488)
  6. Surgery (2392)
  7. Population Sciences Research Program (2339)
  8. Center for Pancreatic Cancer Research (2080)
  9. GSK Faculty (1978)
  10. Department of Pathology and Laboratory Medicine (1573)
  1. "Biostatistics Service"
Formats
  1. Journal Article (3978)
  2. Meeting Abstract (2395)
  3. Research Letter (51)
  4. Conference Paper (37)
  5. Correspondence (26)
  6. Editorial (25)
  7. Review (21)
  8. Miscellaneous (14)
  9. Book Section (13)
  10. Book Whole (3)
  11. Guidelines (2)
Groups
  1. Biostatistics Service (6565)
  2. Epidemiology and Biostatistics (6565)
  3. Department of Medicine (3849)
  4. Solid Tumor Oncology Division (2571)
  5. Survivorship Research (2488)
  6. Surgery (2392)

More Groups

People
  1. Mithat Gonen (1028)
  2. Sean Devlin (601)
  3. Katherine Panageas (512)
  4. Sujata Patil (511)
  5. Sergio Giralt (465)
  6. Zhigang Zhang (427)

More People

Years
  1. 2025 (119)
  2. 2024 (362)
  3. 2023 (411)
  4. 2022 (407)
  5. 2021 (369)
  6. 2020 (394)

More Years

Publications
  1. Journal of Clinical Oncology (1058)
  2. Blood (432)
  3. Annals of Surgical Oncology (308)
  4. International Journal of Radiation Oncology, Biology, Physics (233)
  5. Clinical Cancer Research (195)
  6. Biology of Blood and Marrow Transplantation (174)

More Publications

Publishers
  1. American Society of Clinical Oncology (1124)
  2. Elsevier Inc. (930)
  3. Springer (625)
  4. American Society of Hematology (486)
  5. American Association for Cancer Research (430)
  6. Nature Publishing Group (311)

More Publishers

Results (6565)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL)
    Meeting Abstract

    Ney, D. E.; Reiner, A. S.; Skinner, H. D.; Panageas, K. S.; DeAngelis, L. M.; Abrey, L. E.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Evaluation of the role of aromatase inhibitors (AIs) in the treatment of uterine leiomyosarcoma (uLMS)
    Meeting Abstract

    O'Cearbhaill, R.; Zhou, Q.; Iasonos, A.; Soslow, R. A.; Leitao, M. M. Jr; Aghajanian, C. A.; Hensley, M. L.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience
    Meeting Abstract

    Molina, A. M.; Tickoo, S. K.; Ishill, N.; Trinos, M. J.; Schwartz, L. H.; Russo, P.; Feldman, D. R.; Patil, S.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: Targets for novel personalized therapies
    Meeting Abstract

    Mitsiades, N.; Schultz, N.; Taylor, B. S.; Hieronymus, H.; Satagopan, J.; Scardino, P. T.; Reuter, V. E.; Sander, C.; Sawyers, C.; Scher, H. I.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Kroog, G. S.; Feldman, D. R.; Kondagunta, G. V.; Ginsberg, M. S.; Fischer, P. M.; Trinos, M. J.; Patil, S.; Ishill, N. M.; Motzer, R. J.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel, IP cisplatin, and IV bevacizumab as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer
    Meeting Abstract

    Konner, J. A.; Grabon, D.; Pezzulli, S.; Iasonos, A.; Sabbatini, P.; Hensley, M.; Bell-McGuinn, K.; Tew, W.; Spriggs, D.; Aghajanian, C.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Comparison of cisplatin (CDDP) and radiation (RT) to cetuximab (C) and RT for locally advanced head and neck cancer (LAHNC): A preliminary analysis
    Meeting Abstract

    Koutcher, L.; Fury, M.; Wolden, S.; Zhang, Z.; Mo, Q.; Zelefsky, M.; Kraus, D.; Sherman, E.; Pfister, D.; Lee, N.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Adequate lymph node assessment for extrahepatic bile duct cancer: Do the data support the current AJCC recommendations?
    Meeting Abstract

    Ito, K.; Ito, H.; Gonen, M.; Allen, P. J.; D'Angelica, M. I.; Fong, Y.; DeMatteo, R. P.; Blumgart, L. H.; Jarnagin, W. R.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial
    Meeting Abstract

    Kelsen, D.; Jhawer, M.; Ilson, D.; Tse, A.; Randazzo, J.; Robinson, E.; Capanu, M.; Shah, M. A.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save